miR-152 as a tumor suppressor microRNA: Target recognition and regulation in cancer
Authors:
- 28 April 2016
- journal article
- Published by Spandidos Publications in Oncology Letters
- Vol. 11 (6) , 3911-3916
Abstract
MicroRNAs (miRNAs or miRs) are endogenous translation repressors of protein-coding genes that act by binding to the 3'-untranslated region of their target genes, and may contribute to tumorigenesis by functioning as oncogenes or tumor suppressor genes. miR‑152, a member of the miR-148/152 family, is aberrantly expressed in various diseases, including various types of cancer. A growing body of evidence has demonstrated that miR‑152 may act as a tumor suppressor gene by regulating its target genes, which are associated with cell proliferation, migration and invasion in human cancer. In the present review, the gene structure and functions of miR‑152 are discussed, and in particular, its regulatory mechanism, experimentally validated targets and tumor suppressor role in cancer, are highlighted.Keywords
This publication has 51 references indexed in Scilit:
- The MicroRNA-148/152 Family: Multi-faceted PlayersMolecular Cancer, 2013
- A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1Journal of Molecular Cell Biology, 2012
- MiRNA-Mediated Control of HLA-G Expression and FunctionPLOS ONE, 2012
- MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationshipNature Reviews Genetics, 2012
- Experimental strategies for microRNA target identificationNucleic Acids Research, 2011
- The widespread regulation of microRNA biogenesis, function and decayNature Reviews Genetics, 2010
- Breast Cancer Epigenetics: From DNA Methylation to microRNAsJournal of Mammary Gland Biology and Neoplasia, 2010
- MicroRNAs in CancerAnnual Review of Medicine, 2009
- Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?Nature Reviews Genetics, 2008
- Part I: Chemotherapy for epithelial ovarian cancer–treatment at first diagnosisThe Lancet Oncology, 2002